Russell Investments Group Ltd. Sells 22,111 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Russell Investments Group Ltd. lowered its position in shares of OraSure Technologies, Inc. (NASDAQ:OSURFree Report) by 58.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,968 shares of the medical instruments supplier’s stock after selling 22,111 shares during the period. Russell Investments Group Ltd.’s holdings in OraSure Technologies were worth $131,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of OSUR. Trexquant Investment LP increased its stake in shares of OraSure Technologies by 3.3% in the third quarter. Trexquant Investment LP now owns 64,644 shares of the medical instruments supplier’s stock valued at $383,000 after buying an additional 2,049 shares during the period. Diversified Trust Co increased its position in OraSure Technologies by 17.7% in the 4th quarter. Diversified Trust Co now owns 16,031 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 2,406 shares during the period. Deutsche Bank AG raised its stake in shares of OraSure Technologies by 3.1% during the third quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock valued at $1,165,000 after acquiring an additional 5,875 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of OraSure Technologies by 1.9% during the third quarter. Assenagon Asset Management S.A. now owns 496,796 shares of the medical instruments supplier’s stock worth $2,946,000 after purchasing an additional 9,400 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new stake in shares of OraSure Technologies in the third quarter worth $75,000. 93.50% of the stock is currently owned by institutional investors.

OraSure Technologies Price Performance

NASDAQ OSUR opened at $4.92 on Friday. The stock has a market capitalization of $363.88 million, a P/E ratio of 16.40 and a beta of 0.23. The business has a 50 day simple moving average of $5.64 and a 200 day simple moving average of $6.77. OraSure Technologies, Inc. has a one year low of $4.38 and a one year high of $8.45.

OraSure Technologies (NASDAQ:OSURGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported $0.04 EPS for the quarter, hitting the consensus estimate of $0.04. OraSure Technologies had a net margin of 7.50% and a return on equity of 7.68%. The company had revenue of $54.10 million during the quarter, compared to the consensus estimate of $52.27 million. During the same quarter last year, the firm posted $0.37 EPS. The company’s quarterly revenue was down 65.1% on a year-over-year basis. Equities analysts expect that OraSure Technologies, Inc. will post -0.12 earnings per share for the current year.

Analyst Ratings Changes

OSUR has been the topic of a number of analyst reports. Evercore ISI reduced their price target on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. Finally, JPMorgan Chase & Co. dropped their price target on shares of OraSure Technologies from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Monday, May 13th. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $6.63.

View Our Latest Analysis on OraSure Technologies

OraSure Technologies Profile

(Free Report)

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Featured Stories

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSURFree Report).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.